Abstract
Mammaglobin (SCGB2A2) is a breast-specific member of the secretoglobin (SCGB) gene family. SCGB2A2 has previously been found overexpressed in breast tumors but possible associations between its expression and established prognostic tumor characteristics such as the levels of estrogen and progesterone receptors have not yet been investigated. We evaluated SCGB2A2 expression at the mRNA and at the protein level by reverse-transcription polymerase chain reaction and immunocytochemistry in 52 and 32 breast tumors, respectively. Both SCGB2A2 mRNA and protein expression were significantly higher in estrogen-receptor-positive compared to estrogen-receptor-negative tumors (Mann-Whitney rank sum test, p=0.04; chi-square test, p=0.01; respectively). In contrast, SCGB2A2 expression did not correlate with progesterone receptor levels or Nottingham grade. As estrogen and antiestrogen treatment of estrogen-positive breast cancer cell lines does not modify SCGB2A2 expression we suggest that SCGB2A2 may be a new independent breast cancer prognostic marker.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Watson, M. A. and Fleming, T. P. (1994). Cancer Res. 54, 4598–4602.
Watson, M. A. and Fleming, T. P. (1996). Cancer Res. 56, 860–865.
Leygue, E. R., Watson, P. H., and Murphy, L. C. (1996). Biotechniques 21, 1008–1012.
Leygue, E., Snell, L., Dotzlaw, H., et al. (1999). J. Pathol. 189, 28–33.
Watson, M. A., Dintzis, S., Darrow, C. M., et al. (1999). Cancer Res. 59, 3028–3031.
Zach, O., Kasparu, H., Krieger, O., Hehenwarter, W., Girschikofsky, M., and Lutz, D. (1999). J. Clin. Oncol. 17, 2015–2019.
Zach, O., Wagner, H., Kasparu, H., Krieger, O., and Lutz, D. (2001). Biotechniques 31, 1358–1362.
Gal, S., Fidler, C., Lo, Y. M., et al. (2001). Ann. N.Y. Acad. Sci. 945, 192–194.
Silva, J. M., Dominguez, G., Silva, J., et al. (2001). Clin. Cancer Res. 7, 2821–2825.
Kataoka, A., Mori, M., Sadanaga, N., et al. (2000). Int. J. Oncol. 16, 1147–1152.
Ooka, M., Sakita, I., Fujiwara, Y., et al. (2000). Oncol. Rep. 7, 561–566.
Marchetti, A., Buttitta, F., Bertacca, G., et al. (2001). J. Pathol. 195, 186–190.
Silva, A. L., Tome, M. J., Correia, A. E., and Passos-Coelho, J. L. (2002). Ann. Oncol. 13, 422–429.
Min, C. J., Tafra, L., and Verbanac, K. M. (1998). Cancer Res. 58, 4581–4584.
Moog-Lutz, C., Bouillet, P., Regnier, C. H., et al. (1995). Int. J. Cancer 63, 297–303.
Aapro, M. S. (2001). Oncologist 6, 376–385.
Bundred, N. J. (2001). Cancer Treat Rev. 27, 137–142.
Watson, M. A., Darrow, C., Zimonjic, D. B., Popescu, N. C., and Fleming, T. P. (1998). Oncogene 16, 817–824.
Leygue, E., Gol-Winkler, R., Gompel, A., et al. (1995). J. Steroid Biochem. Mol. Biol. 52, 299–305.
Colpitts, T. L., Billing-Medel, P., Friedman, P., et al. (2001). Biochemistry 40, 11048–11059.
Hiller, T., Snell, L., and Watson, P. H. (1996). Biotechniques 21, 38–44.
Coutts, A. S., Leygue, E., and Murphy, L. C. (1999). J. Mol. Endocrinol. 23, 325–336.
Leygue, E. R., Watson, P. H., and Murphy, L. C. (1996). J. Natl. Cancer Inst. 88, 284–290.
Leygue, E., Snell, L., Hiller, T., et al. (1996). Cancer Res. 56, 4606–4609.
Leygue, E., Snell, L., Dotzlaw, H., et al. (1998). Cancer Res. 58, 1348–1352.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guan, Xf., Hamedani, M.K., Adeyinka, A. et al. Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocr 21, 245–250 (2003). https://doi.org/10.1385/ENDO:21:3:245
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:21:3:245